Maria G. Gomez-Lorenzo

Maria G. Gomez-Lorenzo

Auto-generated profile, based on publicly available information

Maria G. Gomez-Lorenzo

Global Health Medicines R&D, GSK, Tres Cantos, Madrid, Spain

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2004 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
CSChristian Mt Spahn
Christian Mt Spahn
MGMaria G Gomez‐Lorenzo
Maria G Gomez‐Lorenzo
RGRobert A Grassucci
Robert A Grassucci
Rene JørgensenRene Jørgensen
Rene Jørgensen
GAGregers R. Andersen
Gregers R. Andersen
JFJoachim Frank
Joachim Frank
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.

12 January 2018 in Science
Verified
Journal Article
Open access
PDF file
ACAnnie N. Cowell
Annie N. Cowell
EIEva S. Istvan
Eva S. Istvan
ALAmanda K. Lukens
Amanda K. Lukens
MGMaria G. Gomez-Lorenzo
Maria G. Gomez-Lorenzo
MVManu Vanaerschot
Manu Vanaerschot
EWElizabeth A. Winzeler
Elizabeth A. Winzeler
Dissecting Plasmodium drug resistance: Malaria is a deadly disease with no effective vaccine. Physicians thus depend on antimalarial drugs to save lives, but such compounds are often rendered ineffective when parasites evolve resistance. Cowell et al. systematically studied patterns of Plasmodium falciparum genome evolution by analyzing the sequences of clones that were resistant to diverse antimalarial compounds across the P. falciparum life cycle (see the Perspective by Carlton). The findings identify hitherto unrecognized drug targets and drug-resistance genes, as well as additional alleles in known drug-resistance genes. Science , this issue p. 191 ; see also p. 159

1 June 2000 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
MGMaria G. Gomez‐Lorenzo
Maria G. Gomez‐Lorenzo
CSChristian M.T. Spahn
Christian M.T. Spahn
RARajendra K. Agrawal
Rajendra K. Agrawal
RGRobert A. Grassucci
Robert A. Grassucci
PPPawel Penczek
Pawel Penczek
JFJoachim Frank
Joachim Frank
Using a sordarin derivative, an antifungal drug, it was possible to determine the structure of a eukaryotic ribosome·EF2 complex at 17.5 Å resolution by three‐dimensional (3D) cryo‐electron microscopy. EF2 is directly visible in the 3D map and the overall arrangement of the complex from Saccharomyces cerevisiae corresponds to that previously seen in Escherichia coli . However, pronounced differences were found in two prominent regions. First, in the yeast system the interaction between the elongation factor and the stalk region of the large subunit is much more extensive. Secondly, domain IV of EF2 contains additional mass that appears to interact with the head of the 40S subunit and the region of the main bridge of the 60S subunit. The shape and position of domain IV of EF2 suggest that it might interact directly with P‐site‐bound tRNA.

15 June 2016 in Nature Communications
Verified
Journal Article
Open access
VCVictoria C. Corey
Victoria C. Corey
ALAmanda K. Lukens
Amanda K. Lukens
EIEva S. Istvan
Eva S. Istvan
MLMarcus C. S. Lee
Marcus C. S. Lee
VFVirginia Franco
Virginia Franco
EWElizabeth A. Winzeler
Elizabeth A. Winzeler
Microbial resistance to chemotherapy has caused countless deaths where malaria is endemic. Chemotherapy may fail either due to pre-existing resistance or evolution of drug-resistant parasites. Here we use a diverse set of antimalarial compounds to investigate the acquisition of drug resistance and the degree of cross-resistance against common resistance alleles. We assess cross-resistance using a set of 15 parasite lines carrying resistance-conferring alleles in pfatp4, cytochrome bc1, pfcarl, pfdhod, pfcrt, pfmdr, pfdhfr, cytoplasmic prolyl t-RNA synthetase or hsp90. Subsequently, we assess whether resistant parasites can be obtained after several rounds of drug selection. Twenty-three of the 48 in vitro selections result in resistant parasites, with time to resistance onset ranging from 15 to 300 days. Our data indicate that pre-existing resistance may not be a major hurdle for novel-target antimalarial candidates, and focusing our attention on fast-killing compounds may result in a slower onset of clinical resistance.

5 November 2015 in Malaria Journal
Verified
Journal Article
Open access
PDF file
MLMaría Linares
María Linares
SVSara Viera-Morilla
Sara Viera-Morilla
BCBenigno Crespo
Benigno Crespo
VFVirginia Franco
Virginia Franco
MGMaría G. Gómez-Lorenzo
María G. Gómez-Lorenzo
FGFrancisco-Javier Gamo
Francisco-Javier Gamo
The emergence of Plasmodium falciparum resistance to artemisinins threatens to undermine the effectiveness of artemisinin-based combination anti-malarial therapy. Developing suitable drugs to replace artemisinins requires the identification of new compounds that display rapid parasite killing kinetics. However, no current methods fully meet the requirements to screen large compound libraries for candidates with such properties. This study describes the development and validation of an in vitro parasite viability fast assay for identifying rapidly parasiticidal anti-malarial drugs. Parasite killing kinetics were determined by first culturing unlabelled erythrocytes with P. falciparum in the presence of anti-malarial drugs for 24 or 48 h. After removing the drug, samples were added to erythrocytes pre-labelled with intracellular dye to allow their subsequent identification. The ability of viable parasites to re-establish infection in labelled erythrocytes could then be detected by two-colour flow cytometry after tagging of parasite DNA. Thus, double-stained erythrocytes (with the pre-labelled intracellular dye and the parasite DNA dye) result only after establishment of new infections by surviving parasites. The capacity of the test anti-malarial drugs to eliminate viable parasites within 24 or 48 h could, therefore, be determined. The parasite viability fast assay could be completed within 48 h following drug treatment and distinguished between rapidly parasiticidal anti-malarial drugs versus those acting more slowly. The assay was validated against ten standard anti-malarial agents with known properties and results correlated well with established methods. An abbreviated assay, suitable for adaption to medium–high throughput screening, was validated and applied against a set of 20 compounds retrieved from the publically available Medicines for Malaria Venture ‘Malaria Box’. The quantification of new infections to determine parasite viability offers important advantages over existing methods, and is amenable to medium–high throughput screening. In particular, the parasite viability fast assay allows discrimination of rapidly parasiticidal anti-malarial candidates.

1 August 1999 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
JDJuan Manuel Domı́nguez
Juan Manuel Domı́nguez
MGMarı́a G. Gómez-Lorenzo
Marı́a G. Gómez-Lorenzo
JMJ. Julio Martı́n
J. Julio Martı́n
Sordarin derivatives are selective inhibitors of fungal protein synthesis, which specifically impair elongation factor 2 (EF-2) function. We have studied the effect of sordarin on the ribosome-dependent GTPase activity of EF-2 fromCandida albicans in the absence of any other component of the translation system. The effect of sordarin turned out to be dependent both on the ratio of ribosomes to EF-2 and on the nature of the ribosomes. When the amount of EF-2 exceeded that of ribosomes sordarin inhibited the GTPase activity following an inverted bell-shaped dose-response curve, whereas when EF-2 and ribosomes were in equimolar concentrations sordarin yielded a typical sigmoidal dose-dependent inhibition. However, when ricin-treated ribosomes were used, sordarin stimulated the hydrolysis of GTP. These results were compared with those obtained with fusidic acid, showing that both drugs act in a different manner. All these data are consistent with sordarin blocking the elongation cycle at the initial steps of translocation, prior to GTP hydrolysis. In agreement with this conclusion, sordarin prevented the formation of peptidyl-[3H]puromycin on polysomes from Candida albicans.